TF
Tiago Fauth Wells Fargo Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Wave Life Sciences
WVE
$1.3B
| $8.18 | $18 |
120%
upside
| Overweight | yesterday |
|
2
United Therapeutics
UTHR
$17.2B
| $380.47 | $414 |
9%
upside
| Equal-Weight | 2 days ago |
|
3
MannKind Corp
MNKD
$1.64B
| $5.34 | $10 |
87%
upside
| Overweight | 2 days ago |
|
4
Insmed
INSM
$30.1B
| $142.53 | $171 |
20%
upside
| Overweight | 2 days ago |
|
5
PTC Therapeutics
PTCT
$4.61B
| $58.01 | $73 |
26%
upside
| Overweight | 15 days ago |
|
6
Liquidia Corp
LQDA
$2.48B
| $28.84 | $31 |
7%
upside
| Overweight | 23 days ago |
|
7
Alnylam Pharmaceuticals
ALNY
$59.4B
| $453.54 | $395 |
13%
downside
| Equal-Weight | 1 month ago |
|
8
Ultragenyx Pharmaceutical
RARE
$3.01B
| $31.28 | $65 |
108%
upside
| Overweight | 1 month ago |
|
|
VRNA
9
Verona Pharma
VRNA
$9.19B
| $106.24 | $107 |
1%
upside
| Equal-Weight | 1 month ago |
|
10
BridgeBio Pharma
BBIO
$9.91B
| $51.83 | $76 |
47%
upside
| Overweight | 2 months ago |
|
11
Savara
SVRA
$619M
| $3.58 | $7 |
96%
upside
| Overweight | 3 months ago |
|
|
TECX
12
Tectonic Therapeutic, Inc. Common Stock
TECX
$323M
| $17.27 | $101 |
485%
upside
| Overweight | 5 months ago |
|
13
Keros Therapeutics
KROS
$632M
| $15.55 | $26 |
67%
upside
| Overweight | 6 months ago |
|
14
Amicus Therapeutics
FOLD
$2.47B
| $8.02 | $17 |
112%
upside
| Overweight | 6 months ago |
|
15
Disc Medicine
IRON
$2.09B
| $60.19 | $75 |
25%
upside
| Overweight | 1 year ago |
|
16
Ascendis Pharma
ASND
$12B
| $198.13 | $89 |
55%
downside
| Neutral | 2 years ago |
|
|
17
Ultragenyx Pharmaceutical
RARE
$3.01B
| $31.28 | $96 |
207%
upside
| Outperform | 2 years ago |
|
18
Viridian Therapeutics
VRDN
$1.52B
| $18.64 | $51 |
174%
upside
| Outperform | 2 years ago |
|
19
BioMarin Pharmaceuticals
BMRN
$10.9B
| $56.75 | $120 |
111%
upside
| Outperform | 2 years ago |
|
20
Immunovant
IMVT
$2.81B
| $16.12 | $4 |
75%
downside
| Underperform | 2 years ago |
|
21
Absci
ABSI
$359M
| $2.40 | $14 |
483%
upside
| Outperform | 2 years ago |
|
22
Kura Oncology
KURA
$706M
| $8.13 | $26 |
220%
upside
| Outperform | 2 years ago |
|
23
AbCellera Biologics
ABCL
$1.24B
| $4.16 | $28 |
573%
upside
| Outperform | 2 years ago |
|
24
Apellis Pharmaceuticals
APLS
$3.62B
| $28.65 | $81 |
183%
upside
| Neutral | 2 years ago |
|
25
Exelixis
EXEL
$10.1B
| $37.38 | $29 |
22%
downside
| Outperform | 2 years ago |
|